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Introduction: Complicated intra-abdominal infections (cIAIs) are a common cause of morbidity worldwide, and in
spite of improvements in patient care, therapeutic failure still occurs, impacting in-hospital resource consumption.
This study aimed to assess the costs associated with the treatment of community-acquired cIAIs, from the Italian
National Health Service perspective.
Methods: This retrospective study analyzed the charts of patients who were discharged from four Italian university
hospitals between January 1 and December 31, 2009 with a primary diagnosis of community-acquired cIAIs. Patient
characteristics, diagnosis, surgical procedure, antibiotic therapy, and length of hospital stay were all recorded and
the cost of total hospital care was estimated. Costs were calculated in Euros at 2009 values.
Results: The records of 260 patients (mean age 48.9 years; 57% males) were analyzed. The average cost of care
for a patient hospitalized due to cIAI was €4385 (95% CI 3650–5120), with an average daily cost of €419 (95% CI
378–440). Antibiotic therapy represented just under half (44.3%) of hospitalization costs. The strongest predictor of
the increase in hospital costs was clinical failure: patients who clinically failed received an average of 8.2 additional
days of antibiotic therapy and spent 11 more days in hospital compared with patients who responded to first-line
therapy (both p < 0.05 vs. patients who were successfully treated). Furthermore, they incurred €5592 in additional
hospitalization costs (2.88 times the cost associated with clinical success) with 53% (€2973) of the additional
costs attributable to antibiotic therapy. Overall, antibiotic appropriateness rate was 78.8% (n = 205), and was
significantly higher in patients receiving combination therapy compared with those treated with monotherapy
(97.3% vs. 64.6%).
Conclusion: The results of this study suggest that hospitals need to be aware of the clinical and economic
consequences of antibiotic therapy of cIAIs and to reduce overall resource use and costs by improving the rate of
success with appropriate initial empiric therapy.
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Intra-abdominal infections (IAIs), encompassing a wide
spectrum of pathological conditions from uncomplicated
appendicitis to fecal peritonitis, are a common cause of
morbidity worldwide. IAIs are defined as complicated
(cIAIs) when infection extends beyond the affected hol-
low viscus into the peritoneal space, causing either local-
ized or diffuse peritonitis [1]. In spite of improvements
in patient care, therapeutic failure still occurs in patients
with community-acquired (CA) cIAIs [2-5], highly im-
pacting in-hospital resource consumption [2,5,6]. In
early European series, patients with community-acquired
cIAIs who clinically failed had significantly longer length
of hospital stay and incurred significantly higher inpatient
charges than those who were treated successfully [2,6].
More recently, the economic rebound of clinical failure
has been investigated in a large US multi-institutional
database of 6056 patients with cIAIs, showing an add-
itional 4.6 days spent in hospital and inpatient charges of
$6368 when clinical failure occurred [5].
The clinical outcome of patients with cIAIs is heavily
influenced by prompt surgical source control and timely
effective antimicrobial treatment [7,8]. Current guidelines
recommend a wide range of first-line single or multiple
antimicrobial regimens based on patient characteristics
(comorbidities, immunosuppression, and previous anti-
biotic exposure), expected involved pathogens (inferred by
source and origin, community or hospital-acquired, of in-
fection) and local resistance epidemiology [1,5].
Most recent guidelines also consider the antibiotic
treatment of cIAIs from a microbiological point of
view, particularly in terms of pathogens producing ESBLs
(Extended Spectrum Beta-Lactamases). For community-
acquired extrabiliary cIAIs, empirical antimicrobial ther-
apy can be divided into categories: treatment for critically
ill and non-critically ill patients, and treatment for
both groups according to the presence or absence of risk
factors for ESBL-producing pathogens. In non-critically
ill patients, amoxicillin-clavulanate or ciprofloxacin-
metronidazole are possible options, but in the pres-
ence of risk factors for ESBL these are not sufficient,
and other drugs such as tigecycline and ertapenem
are useful. In critically ill patients without risk factors
for ESBL, piperacillin-tazobactam is an option, but in
the presence of ESBL risk factors carbapenems like
imipenem and meropenem are more appropriate [9].
Of note, knowledge of antibiotic drugs costs is suggested
as additional criteria supporting clinical decision-making
[1,5,9]. In fact, in some US and European studies, a signifi-
cant influence of empiric antibiotic therapy choice on eco-
nomic outcome of cIAIs has emerged [3,6,7,10]. However,
the wide inter-country variability of antimicrobial pre-
scribing attitudes and of health care and reimbursement
systems organization could differently impact on costestimates. Therefore, due to this limited generalizability of
data, referring to pharmacoeconomic analyses from other
countries could be misleading.
To the best of our knowledge, a costs analysis of cIAIs
hospital care has never been performed in Italy, although
IAIs have been ranked as the second most common in-
fectious reason for hospitalization, after respiratory
infections [11]. To address this issue, this study aimed
to assess the costs associated with the treatment of
community-acquired cIAIs, from the Italian National
Health Service (i.e. the third payer) perspective.
Methods
Study design
This one-year, multicentre, retrospective, incidence-
based observational study was performed in four Italian
(Bari, Florence, Turin, and Verona) acute-care university
hospitals. The study was conducted in accordance with
the ethical principles of the Declaration of Helsinki (and
subsequent revisions) and to the current norm for obser-
vational studies. The protocol was reviewed and ap-
proved by each study site’s ethical committees. Due to
the retrospective study design, informed consent was
not deemed necessary.
Patient selection
Patients were identified by searching computerized hos-
pitalization records of each recruiting hospital for a pri-
mary discharge diagnoses of one of five International
Classification of Diseases 9th revision (ICD-9) codes sug-
gestive of cIAIs (540.1- acute appendicitis with intra-
abdominal abscess, 540.0 - acute appendicitis with diffuse
peritonitis, 567.2 - other suppurative peritonitis, 567.8-
other specified peritonitis, 567.9 - unspecified peritonitis,
567.0 - peritonitis in infectious disease classified else-
where. Patients were eligible for inclusion if they (1) were
hospitalized between January 1 and December 31, 2009;
(2) were at least 18 years old at the time of their hospi-
talization; (3) had a primary discharge diagnosis suggest-
ing any cIAIs; (4) underwent laparotomy, laparoscopy or
percutaneous drainage of an intra-abdominal abscess and
(5) received intravenous antibiotics.
Patient analysis
A review of each patient’s chart was performed, and rele-
vant parameters were recorded in standardized individ-
ual electronic case report forms. These included: patient
age, gender, comorbidities (diabetes mellitus, obesity or
others), patient lifestyle factors (smoking, alcoholism),
known risk factors for antibiotic failure [1,9] (cancer,
liver cirrhosis, acute liver failure, renal failure, end stage
renal failure, anemia, leukopenia, coagulopathy, immuno-
suppression, or others), primary and secondary discharge
diagnoses, primary surgical procedure and unplanned
Dalfino et al. World Journal of Emergency Surgery 2014, 9:39 Page 3 of 9
http://www.wjes.org/content/9/1/39additional surgeries (if any), laboratory, instrumental and
microbiology tests (number, type and results), antibiotic
therapy type, dose, and duration, switch to second-line
antibiotic drugs and reasons for the switch (clinical failure,
antibiotic resistance, adverse event, unspecified), illness se-
verity markers (use of artificial nutrition, antifungal drugs,
immune globulins, central venous catheter, renal replace-
ment therapies, mechanical ventilation), medical special-
ists’ consultancies (type and frequency), length of hospital
stay, and discharge status (alive/dead). Hospital ward of
admission, in-hospital transfers (to other wards or to the
intensive care unit [ICU]), and place of discharge (home,
other hospitals or long-term care facilities) were also
recorded.Definitions
Primary surgical procedures were categorized according
to the source of infection as surgical operations on up-
per gastrointestinal (GI) tract (biliary or gastro-duodenal
tract, and small intestine), gall-bladder, appendix, lower
GI tract (colon-rectum), peritoneal abscesses drainage,
or others.
Clinical success was defined as patient recovery with
either first line empiric antibiotic therapy or a step-down
from initial therapy (transition wide/narrow spectrum or
intravenous/oral).
Clinical failure was defined as a switch to second-line
antibiotic treatment, need for unscheduled additional ab-
dominal surgeries, or patient death [2-4,6,7].
First-line empiric antibiotic therapy was defined as a
regimen started at the time of surgical intervention, be-
fore the availability of any culture data.
Switch to second-line antibiotic therapy was defined as
the addition of one or more parenteral antibiotics to the
initial antibiotic regimen or as a complete or partial
switch of the initial antibiotic regimen to another paren-
teral antibiotic regimen.
Unscheduled additional abdominal surgeries were ta-
ken into account if they occurred 2 or more days after
the primary surgical procedure and were related to poor
primary source control. Secondary procedures were not
considered in the analysis when there was a mention of
other reasons (i.e. technical issues or hemorrhage) that
might have led to re-operation.
First-line empiric antibiotic therapy was defined as ap-
propriate if all isolated bacteria were sensitive to at least
one of the antibiotics administered in patients with
documented positive intra-abdominal swabs or blood
cultures. Alternatively, in patients with negative or no
cultures, empiric therapy was deemed as appropriate
when the selected regimen covered enteric gram-negative
aerobic and anaerobic bacteria and drug dosing was ad-
equate, according to current guidelines [1]. Antibioticregimens not fulfilling the above criteria were defined as
inappropriate.
Leucocytosis was defined by a white blood cell (WBC)
count >12,000/mm3. Leukopenia was defined as a WBC
count <4000/mm3.
Cost analysis
A estimate of the cost of antibiotics was performed by
multiplying the number of antibiotic days by the unit
price of that antibiotic and by the number of per day
doses. The overall cost of antibiotic treatment for each
patient was the sum of costs calculated for all parenteral
antibiotics received by the patient during the hospi-
talization period. The unit price of antibiotics was based
on official ex-factory prices per unit in Italy [12]. La-
boratory tests, instrumental tests, and specialists’ con-
sultancies utilization were directly recorded and their
costs were assessed by referring to fees for providers of
specialist services recognized by the Italian National
Health Service (I-NHS). Costs related to primary surgi-
cal procedures were not included in analysis, as we as-
sume they were independent of the adopted antibiotic
therapy.
Other direct costs, including personnel, ordinary main-
tenance and hotel costs, were indirectly estimated by
using Diagnosis-Related Group’s tariffs per admission pro-
vided to hospitals by the I-NHS. Specifically, this estimate
was based on the acknowledged over-threshold per hos-
pital day tariff, which is the per day cost to hospitals for
length of stay prolonged over an a priori defined threshold
(i.e. a tariff applicable to length of stay statistically consid-
ered as outliers), assuming that by subtracting the average
costs of specialist services provided from this tariff, an ac-
ceptable proxy of the general cost sustained for patient
management could be obtained.
Costs were expressed in Euro values at the time they
were incurred (year 2009 values).
Statistical analysis
Sample size derived from the number of cIAIs patients
meeting inclusion criteria, admitted at the four recruit-
ing centers from January 1 to December 31, 2009.
Continuous data are expressed as means ± standard
deviation or 95% confidence intervals (CIs), and categor-
ical data as number of events and percentages. Univari-
ate statistical analysis was performed by student t-test or
chi-squared test, as appropriate, to compare baseline
characteristics and outcomes of clinical success and fail-
ure groups.
Due to the retrospective design of the study, a reg-
ression model by means of a backward stepwise model
selection approach was employed to investigate the in-
dependent hospital charges predictors, in order to control
for confounding factors and obtain the exact contribution
Table 1 Demographic and clinical characteristics
Characteristic Patients (n = 260)
Mean ± SD age, years 48.9 ± 20
Males, n (%) 149 (57.3)
Comorbidities, n (%)
Diabetes mellitus 12 (4.6)
Obesity 12 (4.6)
Lifestyle factors, n (%)
Smoking 27 (10.4)
Alcoholism 0 (0)
Therapeutic failure risk factors, n (%)
Age > 65 years 63 (24.2)
Cancer 16 (6.2)
Anemia 16 (6.2)
Liver cirrhosis 1 (0.4)
Renal failure 1 (0.4)
Acute liver failure 0 (0)
End stage renal failure 2 (0.8)
Coagulopathy 2 (0.8)
Immunosuppression 2 (0.8)
Leukopenia 0 (0)
Primary surgical intervention site, n (%)
Appendix 162 (62.3)
Lower GI tract 51 (19.6)
Upper GI tract 13 (5.0)
Gall-bladder 14 (5.4)
Peritoneal abscess 16 (6.1)
Explorative laparotomy/laparoscopy 4 (1.5)
Surgical approach, n (%)
Laparoscopy 135 (51.9)
Laparotomy 116 (44.6)
Percutaneous 9 (3.5)
Illness severity markers, n (%)
Parenteral nutrition 52 (20.0)
Central venous catheter 44 (16.9)
Antifungal drugs 28 (10.8)
Enteral nutrition 22 (8.4)
Invasive mechanical ventilation 20 (7.7)
Immune globulins 0 (0)
Renal replacement therapies 0 (0)
ICU transfer, n (%) 24 (9.2)
Mean ± SD length of hospital stay, days 10.4 ± 13
Mortality rate, n (%) 6 (2.3)
GI, gastrointestinal; ICU, intensive care unit; SD, standard deviation.
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takes into account patient status and controls for type of
primary surgical procedure, unplanned additional surger-
ies, and antibiotic therapy switches. Considered variables
were dummy. In order to avoid co-linearity between vari-
ables, a Pearson correlation was performed. Covariates in
the model were: patient age and gender, one or more high
risk factors, primary surgical procedure, surgical approach,
antibiotic monotherapy/combination therapy, clinical suc-
cess/failure, one or more therapeutic failure risk factors,
unplanned additional surgeries, more than one additional
surgery.
Statistical analyses were performed by using SPSS statis-
tical software version 15.1 (SPSS Inc., Chicago, IL, USA).
A P value <0.05 was considered statistically significant.
Results
Patient characteristics
A total of 260 patients (mean age 48.9 years; 57% males)
met the study entrance criteria. On hospital arrival, 250
(96.2%) patients were admitted to surgical wards, 8
(3.1%) to medical wards, and 2 (0.7%) to the ICU. The
majority of patients (62.3%) were affected by compli-
cated appendicitis. Patients were surgically approached
by laparoscopy in slightly more than half of cases, and
by laparotomy in the majority of the others (Table 1).
One-hundred forty-four (55.4%) patients received first-
line empiric antibiotic therapy as a monotherapy drug
regimen, with the most frequent being ampicillin-sulbac-
tam or amoxicillin-clavulanate (37.5%), and piperacillin-
tazobactam (18.05%; Figure 1). In the remaining 116
(44.6%) patients, who received combination antibiotic
therapy, the most common treatments were amoxicillin-
clavulanate or ampicillin-sulbactam (31.9%), fluoroqui-
nolones (19.8%), or piperacillin-tazobactam (13.8%), all
in combination with metronidazole (Figure 2).
Of the 48 microbiologically evaluable patients (18.4%
of the total patient population), 23 (47.9%) intra-
operative abdominal site cultures (21 peritoneal swabs,
and 2 intra-operative biopsies), 12 (25.0%) abdominal
drainage fluid cultures, 11 (22.9%) blood cultures and 2
(4.2%) surgical wound swabs were performed. Among 34
(70.8%) documented positive cultures, the most frequent
isolated pathogen was Escherichia coli (58.8%), followed
by Klebsiella pneumoniae (14.7%).
Due to the low representation of the microbiological
evaluable population, antibiotic therapy appropriateness
was inferred by covered antimicrobial spectrum and dos-
ing adequacy of starting empiric regimens, as detailed in
the methods section. Overall, antibiotic appropriateness
rate was 78.8% (n = 205), and was significantly higher in
patients receiving combination therapy compared with
those treated with monotherapy (97.3% vs. 64.6%). Clin-
ical success chances with appropriate antibiotic therapy
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Piperacillin-tazobactam
Ampicillin-sulbactam or amoxicillin-
clavulanate
Figure 1 Antibiotics administered to patients who received
monotherapy for first-line treatment of complicated intra-
abdominal infections. Cephalosporins included: cefazolin,
ceftizoxime, cefotaxime, and ceftriaxone; fluoroquinolones included:
ciprofloxacin and levofloxacin; carbapenems included imipenem and
meropenem; aminoglycosides included: amikacin, gentamicin
and tobramycin.
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ate therapy.
In total, 194 (74.6%) patients responded to antibiotic
treatment and experienced clinical success (clinical suc-
cess group), while 66 (25.4%) patients did not respond to31.9
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Ampicillin-sulbactam or Amoxicillin-
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Figure 2 Antibiotic regimens administered to patients who
received combination therapy for the first-line treatment of
complicated intra-abdominal infections. Cephalosporins included:
cefazolin, ceftizoxime, cefotaxime, and ceftriaxone; fluoroquinolones
included: ciprofloxacin and levofloxacin; carbapenems included
imipenem and meropenem; aminoglycosides included: amikacin,
gentamicin and tobramycin. Other regimens included:
aminoglycosides plus ampicillin/sulbactam or piperacillin/
tazobactam, or imipenem (n = 4), fluoroquinolones plus
amoxicillin/clavulanate, cephalosporins, tygecicline or piperacillin/
tazobactam (n = 5), fluoroquinolones plus clindamycin (n = 1).antibiotic therapy (clinical failure group). Ninety-six per
cent (95.8%) of patients were discharged to home, 1.5%
to long-term care facilities, 0.4% to another hospital, and
2.3% died in hospital.
In-hospital charges
The average cost of care for a patient hospitalized due to
cIAI was €4385 (95% CI 3650–5120), with an average
daily cost of €419 (95% CI 378–440). Antibiotic therapy
cost by itself represented just under half (44.3%) of
hospitalization costs. Clinical failure was the strongest
independent predictor of hospitalization costs increases
in multivariable regression analysis, followed by un-
scheduled additional abdominal surgeries, combination
antibiotic therapy administration, patient comorbidities
and illness severity markers (R2 = 0.47) (Table 2).
The critical influence of clinical outcome on hospi-
talization costs prompted us to investigate clinical char-
acteristics and economic outcome of patients stratified
into clinical failure and success groups (Table 3). Com-
pared with the clinical success group, patients in the
clinical failure group were older and were more likely to
have cancer. More patients in the clinical failure group
had undergone lower GI tract surgical procedures, were
surgically approached by laparotomy, and had markers
indicative of severe disease and required ICU transfer
(Table 3). Moreover, they more frequently received anti-
biotic monotherapy (69.7% vs. 52.1%). Specifically, pa-
tients who failed therapy were more like to have received
metronidazole monotherapy (21.4% vs. 3.03%) and were
less likely to have received the combination of fluoroqui-
nolones plus metronidazole (4.7% vs. 22.6%) as their first-
line antibiotic therapy.
The majority of patients who experienced clinical fail-
ure (99.6%) switched to second-line antibiotic therapy,
12 (18.2%) underwent unscheduled additional surgeries
and 6 (9.1%) died. Second-line antibiotic therapy in-
cluded switching to entirely different antibiotics in 63.6%
of cases and addition of one or more drugs to the initial
antibiotic regimen in 36.3% of cases. Reasons for swit-
ching therapy were clinical ineffectiveness in 63.6% of
patients, microbiologic resistance in 9% and was unre-
ported in 24.2% of patients. Second-line regimens involved
meropenem (25.7%), ertapenem (21.2%), tygecicline (19.6%)
and glycopeptides (10.6%).
In-hospital charges by therapeutic outcome
Patients who failed antibiotic therapy received an aver-
age of 8.2 additional days of antibiotic therapy and spent
11 more days in hospital compared with patients who
responded to first-line therapy (both p < 0.05 vs. clinical
success group). Furthermore, they incurred €5592 in add-
itional hospitalization costs (2.88 times the cost associated
with clinical success) with 53% (€2973) of the additional
Table 2 Independent predictors of hospitalization costs associated with complicated intra-abdominal infection
Not standardized
coefficients
Standardized
coefficients
t P
value
Cost
variation (%)
B Standard error Beta
Constant 3,733.00 793.44 4.705 0.000
Clinical failure 3,817.85 681.02 0.275 5.606 0.000 +87.04
Unscheduled secondary surgeries 4,558.00 1,059.75 0.226 4.301 0.000 +104
Antibiotic combination therapy 2,264.09 580.05 0.186 3.903 0.000 +51.6
Comorbidities 2,177.45 742.28 0.14 2.933 0.004 +49.6
Therapeutic failure risk factors 1,755.84 675.91 0.137 2.598 0.010 +40
Appendectomy −3,481.79 698.81 −0.279 −4.982 0.000 −79.4
Cholecystectomy −2,920.24 1,339.50 −0.109 −2.180 0.030 −66.6
Female gender −1,043.09 572.92 −0.085 −1.821 0.070 −23.8
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the other contributors to hospitalization costs were signifi-
cantly higher in the clinical failure group (Figure 3).
A significant cost difference was still found when aver-
age costs per hospital-day were computed, amounting to
€386 (95% CI 350–421) for patients experiencing clinical
success, and €476 (95% CI 414–539) for patients who
failed first-line therapy. Antibiotic cost by itself still was
a great contributor to total per day inpatient charges, in
both success and failure groups (40% and 48.5%, respect-
ively), being significantly higher in patients who failed
starting therapy (€249 vs. €153).
Due to the high contribution of antibiotic therapy to
hospitalization costs, daily charges limited to antibiotic
therapy course duration have been estimated (Figure 4),
and were significantly higher for patients who clinically
failed, as compared to those who succeeded (€502 vs.
€186). This significant extra cost per antibiotic day in
clinical failure cases was confirmed for both single and
multiple drug antibiotic regimens (Figure 4).Discussion
To our knowledge, this is the first multicenter study in-
vestigating the economic outcome of hospitalized cIAIs
in Italy. This study clearly shows that starting empirical
antibiotic therapy has a large impact on the cost of care
of community-acquired cIAIs. In this large sample of
hospitalized adult patients with community-acquired
cIAIs, clinical failure was the strongest independent
predictor of increases in hospitalization costs. Com-
pared with patients who are treated successfully, pa-
tients who failed therapy received antibiotic therapy for
more than one additional week, spent 11 more days in
hospital, and incurred a mean €5600 more in hospital
charges. Antibiotic therapy was the leading contributor
to inpatient charges, and multiple drug regimens was an
independent predictor of increases in costs.Various European and US studies have investigated the
clinical outcomes associated with the treatment of
community-acquired cIAIs and have shown a clinical
failure rate of 17%–35% [2-5], which is consistent with
the 25% failure rate observed in our study. However, very
few studies have addressed the issue of the economic bur-
den of cIAIs.
Early European series have shown that hospitalization
costs are 1.2–1.5 times higher in patients who have failed
treatment compared with patients who were treated
successfully [2,6]. The present study confirms and sub-
stantiates these findings, demonstrating that the costs
associated with failing first-line antibiotic therapy is as-
sociated with a 2.8-fold increase in hospitalization costs
compared with patients who have had clinical success. Im-
portantly, clinical failure was the strongest independent
contributor to inpatient hospitalization charges, leading to
an increase in costs of 87% after adjusting for comorbidi-
ties, therapeutic failure risk factors, type of primary surgi-
cal procedure and unscheduled additional surgeries.
The cost of antibiotic therapy explained over 50% of
total hospitalization charges, confirming previous studies
that have shown that antibiotics contribute 70% of extra
costs associated with cIAIs [6]. This large proportion of
clinical failure costs deriving from antibiotic therapy
most probably arises from the overlap existing between
the failure of antibiotic therapy and clinical failure. Al-
though clinical failure, a widely employed measure of
drug effectiveness [2-4,6,7], is a composite of three dif-
ferent outcomes (antibiotic therapy switch, re-operation
or death), in most instances it is driven by failure of
first-line antibiotic therapy. In our study virtually all pa-
tients who clinically failed required second-line anti-
biotic therapy, while re-operation or death involved only
a few patients (17.7% and 9.1%, respectively). This is
consistent with the results of previous studies which
have shown that the majority of costs associated with
clinical failure are due to antibiotic therapy [2,7].
Table 3 Demographic and clinical characteristics of
patients stratified by clinical outcome
Characteristic Clinical success
group (n = 194)
Clinical failure
group (n = 66)
P value
Mean ± SD age, years 46.4 ± 19 56.2 ± 21 <0.05
Males, n (%) 113 (58.2) 36 (54.5) NS
Comorbidities, n (%)
Diabetes mellitus 7 (3.6) 5 (7.5) NS
Obesity 9 (4.6) 3 (4.5) NS
Lifestyle factors, n (%)
Smoking 22 (11.3) 5 (7.5) NS
Alcoholism 0 (0) 0 (0) NS
Therapeutic failure risk
factors, n (%)
Age > 65 years 38 (19.5) 25 (37.8) <0.05
Cancer 8 (4.1) 8 (12.1) <0.05
Anemia 6 (3.1) 10 (15.2) <0.05
Liver cirrhosis 1 (0.5) 0 (0) NS
Renal failure 1 (0.5) 1 (1.5) NS
End stage renal failure 2 (1.0) 0 (0) NS
Coagulopathy 2 (1.0) 0 (0) NS
Immunosuppression 1 (0.5) 1 (1.5) NS
Primary surgical
intervention site, n (%)
Appendix 132 (68.0) 30 (45.4) <0.05
Lower GI tract 23 (11.8) 28 (42.4) <0.05
Upper GI tract 10 (5.1) 3 (4.5) NS
Gall-bladder 13 (6.7) 1 (1.5) NS
Peritoneal abscess 13 (6.7) 3 (4.5) NS
Other 3 (1.5) 1 (1.5) NS
Surgical approach, n (%)
Laparoscopy 111 (57.2) 24 (36.3) <0.05
Laparotomy 76 (39.2) 40 (60.6) <0.05
Percutaneous 7 (3.6) 2 (3.0) NS
Antibiotic treatment, n (%)
Monotherapy 101 (52.1) 46 (69.7) <0.05
Combination therapy 93 (47.9) 20 (30.3) <0.05
Illness severity markers, n (%)
Parenteral nutrition 27 (13.9) 25 (37.8) <0.05
Central venous catheter 16 (8.2) 24 (36.3) <0.05
Antifungal drugs 12 (6.2) 16 (24.2) <0.05
Enteral nutrition 10 (5.2) 12 (18.2) <0.05
Invasive mechanical
ventilation
6 (3.1) 14 (21.2) <0.05
ICU admission, n (%) 6 (3.1) 18 (27.3) <0.05
Mortality rate, n (%) 0 (0) 6 (9.1) NS
GI, gastrointestinal; ICU, intensive care unit; NS, not significant; SD,
standard deviation.
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driven by unsuitable drug choice [3,4,6]. In the present
study, although only “presumed” basing on drug spec-
trum of coverage adequacy [1], appropriate antibiotic
therapy was associated with a 78% chance of clinical suc-
cess, compared with a 34% chance of clinical success as-
sociated with inappropriate therapy. Therefore, the role
of antibiotic failure and inappropriateness of drug choice
having a large influence on the occurrence of clinical fail-
ure could be inferred, as previously demonstrated [3,7,10].
As expected, the appropriateness of empiric antibiotic
therapy was more frequently reached with wide spec-
trum combination therapy. We found that multiple-drug
empiric regimens were appropriate in 97% of cases com-
pared with roughly 65% of single drug regimens. More-
over, patients who achieved clinical success were more
likely to have received antibiotic combination therapy
than those patients who failed antibiotic therapy, con-
firming previous findings [7]. On the other hand, the
costs per day of antibiotic combination regimens were
significantly higher than the costs of antibiotic mono-
therapy, regardless of therapeutic outcome. Importantly,
combination therapy was a strong independent predictor
of increases in inpatient charges, causing approximately
a 50% increase of mean hospitalization costs. Thus, the
benefit/cost ratio underpinning the correct management
of community-acquired cIAIs seems to be difficult to
balance.
Multiple antibiotic regimens aim to expand antimicro-
bial spectrum and to overcome increased bacterial resist-
ance in community-acquired cIAIs [13,14]. Recently,
newly introduced wide spectrum agents, such as ertape-
nem and tygecicline, have been recommended [8] for
use as first-line empiric antibiotic monotherapy re-
gimens in stable, noncritically ill cIAIs patients with
extended-spectrum beta-lactamase producing pathogens
risk factors, factors that are becoming more frequently
involved in community-acquired cIAIs [13,14]. Interest-
ingly, these were also among the most frequent second-
line choices in our failing patients, underlying the cost/
benefit advantage of such recommendation.
As previously reported [2,6,7], patients who were less
healthy due to an increased age, comorbidities or those
with known treatment failure risk factors, were signifi-
cantly more likely to fail antibiotic therapy. These same
features independently increased hospitalization costs.
Therefore, illness severity must be strongly considered
when choosing starting empirical antibiotic therapy, due
to its influence on clinical and economic outcomes of
patients with cIAIs.
The low rate of intra-operative microbiology tests per-
formed in the present study is worrisome. As choosing an-
tibiotics for the treatment of cIAIs is an empiric decision,
local epidemiology knowledge is of outmost importance.
0 1000 2000 3000 4000 5000 6000 7000 8000 9000
Total
Antibiotic therapy
Laboratory tests
Instrumental tests
Consultancies
Other direct costs
Costs (€)
Clinical success group (n = 194)
Clinical failure group (n = 66)
€2966 (2484–3447)*
€8558 (6254–10862) 
€1188 (883–1493)*
€4161 (2947–5374)
€111 (97–124)*
€287 (203–371)
€284 (166–401)*
€599 (197–1000)
€5.7 (3.2–8)*
€26 (17–36)
€1376 (1185–1567)*
€3483 (2520–4446)
Figure 3 Total hospitalization costs per patient, stratified by therapeutic outcome. Other direct costs category includes personnel,
ordinary maintenance and hotel costs. *p < 0.05 vs. clinical failure group.
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http://www.wjes.org/content/9/1/39By increasing the chance of appropriate treatment [1], it
could improve outcome and decrease resource utilization
in patients subsequently hospitalized in the same institu-
tion for the same condition. Thus, we recommend that
the consistent taking of swab samples by Italian surgeons
is implemented.
As with any retrospective analysis, this study has sev-
eral limitations. Due to complexities associated with the
collection of data, summary measures of illness and co-
morbidities severity, potentially associated with clinical
failure, longer length of hospital stay, and higher inpa-
tient costs were not covered and could not be used in
the multivariate model. We were also unable to assess the
appropriateness of antibiotic therapy in light of culture0 100 200
Therapeutic success
Therapeutic failure
Therapeutic success with
monotherapy
Therapeutic success with
combination therapy
Therapeutic failure with
monotherapy
Therapeutic failure with
combination therapy
€186
€75 (45  105)
Figure 4 Hospitalization costs per day of antibiotic therapy in patient
*p < 0.05 vs. clinical failure group; #p < 0.05 vs. antibiotic monotherapy grouresults and patient clinical risk profile [1,9] and, therefore,
the clinical failure variable, rather than antibiotic appro-
priateness, was used in the multivariable analysis of in-
dependent cost predictors. Finally, being a multicenter
study, dissimilarity in standard of care among participating
sites cannot be excluded.
Despite these limitations, for the first time we assessed
patterns of starting antibiotic therapy, resource utilization
and actual costs of caring for inpatients with community-
acquired cIAIs in Italian hospitals. The results of this
study suggest that hospitals need to be aware of the clin-
ical and economic consequences of antibiotic therapy and
to reduce overall resource use and costs by improving the
rate of success with appropriate initial empiric therapy.300 400 500 600 700
Costs (€)
Clinical success group (n = 194)
Clinical failure group (n = 66)
 (148  224)
€502 (400  606)*
€428 (294  563)
€307 (242  372)#
€642 (490  795)#
s stratified by therapeutic outcome and antibiotic regimens.
p.
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http://www.wjes.org/content/9/1/39Considering the prospective reimbursement system of the
Italian NHS, there may be a relevant cost saving at the
same reimbursement rate for hospitals, by reducing anti-
biotic costs of cIAIs. Mandatory peritoneal swab sampling,
allowing for local epidemiology driven empiric antibiotic
therapy, should be strongly encouraged for each cIAIs
patient.
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